Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Pantoprazole does not reduce upper gastrointestinal bleeding during anticoagulation treatment

07 Aug 2019

Proton pump inhibitor therapy, particularly with pantoprazole, does not reduce upper gastrointestinal bleeding events in patients taking low-dose anticoagulation/aspirin treatment, reports a recent study.

Researchers randomly assigned 17,598 patients with stable cardiovascular and peripheral artery disease to receive either daily 40-mg pantoprazole (n=8,791; mean age, 67.6±8.1 years; 22 percent female) or placebo (n=8,807; mean age, 67.7±8.1 years; 21 percent female). Participants were also given rivaroxaban 2.5 mg twice daily with 100-mg aspirin once daily, rivaroxaban 5 mg twice daily or aspirin 100 mg alone.

The primary efficacy outcome of clinically significant events in the upper gastrointestinal tract occurred in 1.2 percent (n=102) of the pantoprazole arm and in 1.3 percent (n=116) of the placebo group. The difference did not reach significance (hazard ratio [HR], 0.88, 95 percent CI, 0.67–1.15).

Further analysis according to the components of upper gastrointestinal bleeding showed that both treatment arms were comparable in terms of overt or occult bleeding events. However, the likelihood of gastroduodenal bleeding was significantly attenuated in patients who were given pantoprazole (HR, 0.52, 0.28–0.94; p=0.03).

In a subsequent posthoc analysis where the definition of bleeding events was broadened, pantoprazole use remained significantly associated with a lower risk of bleeding of gastroduodenal lesions (HR, 0.45, 0.27–0.74). Pantoprazole also exerted a significant protective effect against peptic ulcer (HR, 0.46, 0.25–0.83) and erosions (HR, 0.13–0.84).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).